세계의 폐렴구균 백신 시장 : 산업 규모, 점유율, 동향, 기회, 예측 - 유형별, 적응증별, 제품별, 유통별, 지역별, 경쟁별(2020-2030년)

Pneumococcal Vaccine Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Type, By Indication, By Product, By Distribution, By Region & Competition, 2020-2030F

US $ 4,500 ￦ 6,358,000

Unprintable PDF (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 불가능하며, 텍스트의 Copy&Paste도 불가능합니다.

US $ 5,500 ￦ 7,771,000

PDF and Excel (Multi-User License)

PDF 및 Excel 보고서를 기업의 팀이나 기관에서 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 및 Excel 이용 범위와 동일합니다.

US $ 8,000 ￦ 11,304,000

PDF and Excel (Custom Research License)

PDF 및 Excel 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 및 Excel 이용 범위와 동일합니다. 80시간의 애널리스트 타임이 포함되어 있고 Copy & Paste 가능한 PPT 버전도 제공됩니다. 짧은 Bespoke 리서치 프로젝트 수행에 맞는 라이선스입니다.

한글목차

세계의 폐렴구균 백신 시장 규모는 2024년에 96억 3,000만 달러로 평가되었고, 예측 기간에는 2030년까지 연평균 복합 성장률(CAGR) 6.26%로 눈부신 성장이 예측되고 있습니다.

세계의 폐렴구균 백신 시장은 의약품 및 헬스케어 산업의 중요한 부문이며, 주로 폐렴구균에 의한 감염증의 예방을 목적으로 하고 있습니다. 폐렴구균 감염은 폐렴, 수막염, 패혈증 등 다양한 질병을 유발할 수 있으며, 특히 유아와 노인에게는 공중 보건에 심각한 위협이 되고 있습니다. 예를 들어, WHO의 2023년 추계에 따르면, 폐렴구균 감염은 매년 세계 약 160만 명의 사망을 일으키며, 그 중 약 100만 명이 5세 미만의 소아에서 사망합니다. 어린이의 사망률에 큰 영향을 미치기 때문에 WHO는 폐렴구균 감염을 예방 접종의 우선 순위가 높은 질병으로 간주합니다. 이에 대응하기 위해 WHO는 효과적인 예방책으로 13가 폐렴구균 결합 백신(PCV)의 사용을 강력히 권장하고 있습니다. 이러한 백신은 특히 헬스케어에 대한 접근이 제한되고 질병의 만연률이 높은 지역에서 유아의 폐렴, 수막염, 패혈증과 같은 심각한 감염을 감소시키는 데 중요한 역할을 합니다.

시장 개요
예측 기간	2026-2030년
시장 규모(2024년)	96억 3,000만 달러
시장 규모(2030년)	137억 5,000만 달러
CAGR(2025-2030년)	6.26%
급성장 부문	혼합 백신
최대 시장	북미

시장 성장 촉진요인

폐렴 구균 감염에 대한 세계의 의식 증가

주요 시장 과제

경제 격차

주요 시장 동향

차세대 백신

목차

제1장 개요

제2장 조사 방법

제3장 주요 요약

제4장 고객의 목소리

제5장 세계의 폐렴구균 백신 시장 전망

• 시장 규모 및 예측
  • 금액별
• 시장 점유율 및 예측
  • 유형별(결합 백신, 다당체 백신)
  • 적응증별(기관지염, 수막염, 폐렴, 패혈증)
  • 제품별(Pneumovax23, Prevnar 13, Synflorix)
  • 분포별(정부기관, 비정부조직)
  • 지역별
  • 기업별(2024년)
• 제품 시장 맵
  • 유형별
  • 적응증별
  • 제품별
  • 배포처별
  • 지역별

제6장 북미의 폐렴구균 백신 시장 전망

• 시장 규모 및 예측
• 시장 점유율 및 예측
• 북미 : 국가별 분석
  • 미국
  • 캐나다
  • 멕시코

제7장 유럽의 폐렴구균 백신 시장 전망

• 시장 규모 및 예측
• 시장 점유율 및 예측
• 유럽 : 국가별 분석
  • 독일
  • 영국
  • 프랑스
  • 이탈리아
  • 스페인

제8장 아시아태평양의 폐렴구균 백신 시장 전망

• 시장 규모 및 예측
• 시장 점유율 및 예측
• 아시아태평양 : 국가별 분석
  • 중국
  • 일본
  • 인도
  • 호주
  • 한국

제9장 남미의 폐렴구균 백신 시장 전망

• 시장 규모 및 예측
• 시장 점유율 및 예측
• 남미 : 국가별 분석
  • 브라질
  • 아르헨티나
  • 콜롬비아

제10장 중동 및 아프리카의 폐렴구균 백신 시장 전망

• 시장 규모 및 예측
• 시장 점유율 및 예측
• 중동 및 아프리카 : 국가별 분석
  • 남아프리카
  • 사우디아라비아
  • 아랍에미리트(UAE)
  • 쿠웨이트

제11장 시장 역학

• 성장 촉진요인
• 과제

제12장 시장 동향 및 발전

• 최근 동향
• 합병 및 인수
• 제품 출시

제13장 Porter's Five Forces 분석

• 업계 내 경쟁
• 신규 진입의 가능성
• 공급자의 힘
• 고객의 힘
• 대체품의 위협

제14장 경쟁 구도

• GSK PLC
• Pfizer Inc
• Merck KGaA
• Serum Institute of India Pvt Ltd
• CSL Ltd
• Sanofi SA
• Walvax Biotechnology Co., Ltd
• Beijing Minhai Biotechnology Limited Company
• AstraZeneca PLC
• BioNTech

제15장 전략적 제안

제16장 기업 소개 및 면책사항

AJY

영문 목차

영문목차

Global Pneumococcal Vaccine Market was valued at USD 9.63 billion in 2024 and is anticipated to project impressive growth in the forecast period with a CAGR of 6.26% through 2030. The global pneumococcal vaccine market is a crucial segment of the pharmaceutical and healthcare industry, primarily aimed at preventing infections caused by Streptococcus pneumoniae bacteria. Pneumococcal infections can lead to various illnesses, including pneumonia, meningitis, and sepsis, and they pose a significant public health threat, particularly to young children and the elderly. For instance, according to WHO estimates in 2023, pneumococcal infections cause approximately 1.6 million deaths worldwide each year, with nearly one million fatalities occurring in children under the age of five. Given its significant impact on child mortality, WHO classifies pneumococcal disease as a high-priority condition for vaccination. To combat this, the organization strongly recommends the use of 13-valent pneumococcal conjugate vaccines (PCVs) as an effective preventive measure. These vaccines play a crucial role in reducing severe infections such as pneumonia, meningitis, and sepsis in young children, particularly in regions with limited healthcare access and high disease prevalence.

Market Overview
Forecast Period	2026-2030
Market Size 2024	USD 9.63 Billion
Market Size 2030	USD 13.75 Billion
CAGR 2025-2030	6.26%
Fastest Growing Segment	Conjugate Vaccines
Largest Market	North America

Key Market Drivers

Rising Global Awareness of Pneumococcal Diseases

One of the fundamental reasons behind the growth of the pneumococcal vaccine market is the increasing understanding of the serious health consequences posed by pneumococcal diseases. Medical professionals, policymakers, and the general public are becoming more aware of the debilitating and potentially fatal nature of these infections, leading to a heightened sense of urgency in preventing them. For instance, in June 2023, Sanofi and SK bioscience announced positive results from phase II clinical trials of their 21-valent conjugate vaccine candidate. The findings suggest that GBP410 may provide broader serotype coverage compared to existing vaccines, potentially expanding its market share. Based on these promising results, the companies plan to advance to phase III trials in 2024, with the goal of obtaining final data by 2027.

Public health organizations and advocacy groups have played a pivotal role in disseminating information about pneumococcal diseases. Their efforts include educational campaigns, public service announcements, and initiatives that emphasize the importance of vaccination. As individuals become better informed, they are more likely to seek out and request pneumococcal vaccines.

Key Market Challenges

Economic Disparities

One of the most prominent challenges is the economic disparity among nations. High-income countries often have better access to pneumococcal vaccines due to robust healthcare infrastructures and funding. In contrast, low- and middle-income countries struggle to afford these vaccines, leading to unequal access and health disparities.

Key Market Trends

Next-Generation Vaccines

Advancements in vaccine technology are paving the way for next-generation pneumococcal vaccines. These vaccines are designed to offer broader protection against a wider range of pneumococcal serotypes. By harnessing innovative formulations and targeting evolving bacterial strains, next-gen vaccines are poised to enhance vaccine effectiveness and durability.

Key Market Players

• GSK PLC
• Pfizer Inc
• Merck KGaA
• Serum Institute of India Pvt Ltd
• CSL Ltd
• Sanofi SA
• Walvax Biotechnology Co., Ltd
• Beijing Minhai Biotechnology Limited Company
• AstraZeneca PLC
• BioNTech

Report Scope:

In this report, the Global Pneumococcal Vaccine Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Pneumococcal Vaccine Market, By Type:

• Conjugate Vaccines
• Polysaccharide Vaccines

Pneumococcal Vaccine Market, By Indication:

• Bronchitis
• Meningitis
• Pneumonia
• Sepsis

Pneumococcal Vaccine Market, By Product:

• Pneumovax23
• Prevnar 13
• Synflorix

Pneumococcal Vaccine Market, By Distribution:

• Government Authorities
• Non-Governmental Organizations

Pneumococcal Vaccine Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • Germany
  • United Kingdom
  • France
  • Italy
  • Spain
• Asia-Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Pneumococcal Vaccine Market.

Available Customizations:

Global Pneumococcal Vaccine market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Pneumococcal Vaccine Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Type (Conjugate Vaccines, Polysaccharide Vaccines)
  • 5.2.2. By Indication (Bronchitis, Meningitis, Pneumonia, Sepsis)
  • 5.2.3. By Product (Pneumovax23, Prevnar 13, Synflorix)
  • 5.2.4. By Distribution (Government Authorities, Non-Governmental Organizations)
  • 5.2.5. By Region
  • 5.2.6. By Company (2024)
• 5.3. Product Market Map
  • 5.3.1. By Type
  • 5.3.2. By Indication
  • 5.3.3. By Product
  • 5.3.4. By Distribution
  • 5.3.5. By Region

6. North America Pneumococcal Vaccine Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Type (Conjugate Vaccines, Polysaccharide Vaccines)
  • 6.2.2. By Indication (Bronchitis, Meningitis, Pneumonia, Sepsis)
  • 6.2.3. By Product (Pneumovax23, Prevnar 13, Synflorix)
  • 6.2.4. By Distribution (Government Authorities, Non-Governmental Organizations)
  • 6.2.5. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Pneumococcal Vaccine Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Type
      • 6.3.1.2.2. By Indication
      • 6.3.1.2.3. By Product
      • 6.3.1.2.4. By Distribution
  • 6.3.2. Canada Pneumococcal Vaccine Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Type
      • 6.3.2.2.2. By Indication
      • 6.3.2.2.3. By Product
      • 6.3.2.2.4. By Distribution
  • 6.3.3. Mexico Pneumococcal Vaccine Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Type
      • 6.3.3.2.2. By Indication
      • 6.3.3.2.3. By Product
      • 6.3.3.2.4. By Distribution

7. Europe Pneumococcal Vaccine Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Type (Conjugate Vaccines, Polysaccharide Vaccines)
  • 7.2.2. By Indication (Bronchitis, Meningitis, Pneumonia, Sepsis)
  • 7.2.3. By Product (Pneumovax23, Prevnar 13, Synflorix)
  • 7.2.4. By Distribution (Government Authorities, Non-Governmental Organizations)
  • 7.2.5. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Pneumococcal Vaccine Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Type
      • 7.3.1.2.2. By Indication
      • 7.3.1.2.3. By Product
      • 7.3.1.2.4. By Distribution
  • 7.3.2. United Kingdom Pneumococcal Vaccine Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Type
      • 7.3.2.2.2. By Indication
      • 7.3.2.2.3. By Product
      • 7.3.2.2.4. By Distribution
  • 7.3.3. France Pneumococcal Vaccine Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Type
      • 7.3.3.2.2. By Indication
      • 7.3.3.2.3. By Product
      • 7.3.3.2.4. By Distribution
  • 7.3.4. Italy Pneumococcal Vaccine Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Type
      • 7.3.4.2.2. By Indication
      • 7.3.4.2.3. By Product
      • 7.3.4.2.4. By Distribution
  • 7.3.5. Spain Pneumococcal Vaccine Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Type
      • 7.3.5.2.2. By Indication
      • 7.3.5.2.3. By Product
      • 7.3.5.2.4. By Distribution

8. Asia-Pacific Pneumococcal Vaccine Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Type (Conjugate Vaccines, Polysaccharide Vaccines)
  • 8.2.2. By Indication (Bronchitis, Meningitis, Pneumonia, Sepsis)
  • 8.2.3. By Product (Pneumovax23, Prevnar 13, Synflorix)
  • 8.2.4. By Distribution (Government Authorities, Non-Governmental Organizations)
  • 8.2.5. By Country
• 8.3. Asia-Pacific: Country Analysis
  • 8.3.1. China Pneumococcal Vaccine Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Type
      • 8.3.1.2.2. By Indication
      • 8.3.1.2.3. By Product
      • 8.3.1.2.4. By Distribution
  • 8.3.2. Japan Pneumococcal Vaccine Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Type
      • 8.3.2.2.2. By Indication
      • 8.3.2.2.3. By Product
      • 8.3.2.2.4. By Distribution
  • 8.3.3. India Pneumococcal Vaccine Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Type
      • 8.3.3.2.2. By Indication
      • 8.3.3.2.3. By Product
      • 8.3.3.2.4. By Distribution
  • 8.3.4. Australia Pneumococcal Vaccine Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Type
      • 8.3.4.2.2. By Indication
      • 8.3.4.2.3. By Product
      • 8.3.4.2.4. By Distribution
  • 8.3.5. South Korea Pneumococcal Vaccine Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Type
      • 8.3.5.2.2. By Indication
      • 8.3.5.2.3. By Product
      • 8.3.5.2.4. By Distribution

9. South America Pneumococcal Vaccine Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Type (Conjugate Vaccines, Polysaccharide Vaccines)
  • 9.2.2. By Indication (Bronchitis, Meningitis, Pneumonia, Sepsis)
  • 9.2.3. By Product (Pneumovax23, Prevnar 13, Synflorix)
  • 9.2.4. By Distribution (Government Authorities, Non-Governmental Organizations)
  • 9.2.5. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Pneumococcal Vaccine Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Type
      • 9.3.1.2.2. By Indication
      • 9.3.1.2.3. By Product
      • 9.3.1.2.4. By Distribution
  • 9.3.2. Argentina Pneumococcal Vaccine Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Type
      • 9.3.2.2.2. By Indication
      • 9.3.2.2.3. By Product
      • 9.3.2.2.4. By Distribution
  • 9.3.3. Colombia Pneumococcal Vaccine Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Type
      • 9.3.3.2.2. By Indication
      • 9.3.3.2.3. By Product
      • 9.3.3.2.4. By Distribution

10. Middle East and Africa Pneumococcal Vaccine Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Type (Conjugate Vaccines, Polysaccharide Vaccines)
  • 10.2.2. By Indication (Bronchitis, Meningitis, Pneumonia, Sepsis)
  • 10.2.3. By Product (Pneumovax23, Prevnar 13, Synflorix)
  • 10.2.4. By Distribution (Government Authorities, Non-Governmental Organizations)
  • 10.2.5. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Pneumococcal Vaccine Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Type
      • 10.3.1.2.2. By Indication
      • 10.3.1.2.3. By Product
      • 10.3.1.2.4. By Distribution
  • 10.3.2. Saudi Arabia Pneumococcal Vaccine Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Type
      • 10.3.2.2.2. By Indication
      • 10.3.2.2.3. By Product
      • 10.3.2.2.4. By Distribution
  • 10.3.3. UAE Pneumococcal Vaccine Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Type
      • 10.3.3.2.2. By Indication
      • 10.3.3.2.3. By Product
      • 10.3.3.2.4. By Distribution
  • 10.3.4. Kuwait Pneumococcal Vaccine Market Outlook
    • 10.3.4.1. Market Size & Forecast
      • 10.3.4.1.1. By Value
    • 10.3.4.2. Market Share & Forecast
      • 10.3.4.2.1. By Type
      • 10.3.4.2.2. By Indication
      • 10.3.4.2.3. By Product
      • 10.3.4.2.4. By Distribution

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Recent Development
• 12.2. Mergers & Acquisitions
• 12.3. Product Launches

13. Porter's Five Forces Analysis

• 13.1. Competition in the Industry
• 13.2. Potential of New Entrants
• 13.3. Power of Suppliers
• 13.4. Power of Customers
• 13.5. Threat of Substitute Products

14. Competitive Landscape

• 14.1. GSK PLC
  • 14.1.1. Business Overview
  • 14.1.2. Product Offerings
  • 14.1.3. Recent Developments
  • 14.1.4. Financials (As Reported)
  • 14.1.5. Key Personnel
  • 14.1.6. SWOT Analysis
• 14.2. Pfizer Inc
• 14.3. Merck KGaA
• 14.4. Serum Institute of India Pvt Ltd
• 14.5. CSL Ltd
• 14.6. Sanofi SA
• 14.7. Walvax Biotechnology Co., Ltd
• 14.8. Beijing Minhai Biotechnology Limited Company
• 14.9. AstraZeneca PLC
• 14.10. BioNTech

15. Strategic Recommendations

16. About Us & Disclaimer

관련자료